Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1464032

University of Nebraska - Developmental Therapeutics Review - Q4 2010

Description:
University of Nebraska – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “University of Nebraska – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by University of Nebraska.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of University of Nebraska with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of University of Nebraska’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in University of Nebraska’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate University of Nebraska’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of University of Nebraska in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with University of Nebraska.
- Avoid Intellectual Property Rights related issues.
 
Contents:


List of Tables
List of Figures
University of Nebraska Snapshot
University of Nebraska Overview
Key Information
Key Facts
University of Nebraska – Research and Development Overview
Key Therapeutic Areas
University of Nebraska – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
University of Nebraska – Pipeline Products Glance
University of Nebraska – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
University of Nebraska Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
University of Nebraska – Drug Profiles
Autologous platelet gel
Product Description
Mechanism of Action
R&D Progress
Doxycycline
Product Description
Mechanism of Action
R&D Progress
Leflunomide
Product Description
Mechanism of Action
R&D Progress
Leflunomide + Sulfasalazine + Hydroxychloroquine
Product Description
Mechanism of Action
R&D Progress
Methotrexate
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Sulfasalazine + Hydroxychloroquine
Product Description
Mechanism of Action
R&D Progress
Minocycline + Methotrexate
Product Description
Mechanism of Action
R&D Progress
Minocycline + MTX
Product Description
Mechanism of Action
R&D Progress
Rituxan + CHOP Chemotherapy
Product Description
Mechanism of Action
R&D Progress
Anti-thymocyte globulin + Busulfan + Cyclophosphamide + Mycophenolate mofetil + Tacrolimus
Product Description
Mechanism of Action
R&D Progress
Autologous Tumor Cell Vaccine + Keyhole Limpet Hemocyanin + Sargramostim
Product Description
Mechanism of Action
R&D Progress
BEAM + Rituximab + Autologous Hematopoietic Stem Cell Transplantation + Lenalidomide
Product Description
Mechanism of Action
R&D Progress
bevacizumab + pegfilgrastim + cyclophosphamide + doxorubicin hydrochloride + gemcitabine hydrochloride + paclitaxel
Product Description
Mechanism of Action
R&D Progress
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Allogeneic Hematopoietic Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Cytarabine + G-CSF
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + paclitaxel + trastuzumab
Product Description
Mechanism of Action
R&D Progress
Dasatinib_
Product Description
Mechanism of Action
R&D Progress
etoposide + gefitinib
Product Description
Mechanism of Action
R&D Progress
filgrastim + capecitabine + celecoxib + cyclophosphamide + docetaxel + doxorubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
filgrastim + capecitabine + celecoxib + cyclophosphamide + docetaxel + doxorubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
filgrastim + clofarabine + cytarabine
Product Description
Mechanism of Action
R&D Progress
filgrastim + clofarabine + cytarabine
Product Description
Mechanism of Action
R&D Progress
filgrastim + pegfilgrastim + cisplatin + cytarabine + etoposide + methylprednisolone
Product Description
Mechanism of Action
R&D Progress
filgrastim + sargramostim + carmustine + cyclophosphamide + cytarabine + etoposide
Product Description
Mechanism of Action
R&D Progress
filgrastim + sargramostim + carmustine + cyclophosphamide + cytarabine + etoposide
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Gemcitabine + Leucovorin + Oxaliplatin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Keyhole limpet hemocyanin + Sargramostim + Tumor cell-based vaccine therapy + Cyclophosphamide + Doxorubicin hydrochloride + Mitoxantrone hydrochloride + Prednisone + Vincristine sulfate
Product Description
Mechanism of Action
R&D Progress
Keyhole limpet hemocyanin + Sargramostim + Tumor cell-based vaccine therapy + Cyclophosphamide + Doxorubicin hydrochloride + Mitoxantrone hydrochloride + Prednisone + Vincristine sulfate
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Ofatumumab
Product Description
Mechanism of Action
R&D Progress
lenalidomide + rituximab + autologous hematopoietic stem cell + carmustine + etoposide + cytarabine + melphalan
Product Description
Mechanism of Action
R&D Progress
Omegaven
Product Description
Mechanism of Action
R&D Progress
paclitaxel + cyclophosphamide + doxorubicin + autologous dendritic cells + radiation theraphy
Product Description
Mechanism of Action
R&D Progress
paclitaxel + vinorelbine ditartrate
Product Description
Mechanism of Action
R&D Progress
Rituxan + BEAM + Autologous stem cell transplant
Product Description
Mechanism of Action
R&D Progress
Rituximab + Carboplatin + Etoposide + Ifosfamide
Product Description
Mechanism of Action
R&D Progress
Rituximab + carmustine + cytarabine + etoposide + melphalan + autologous bone marrow transplantation
Product Description
Mechanism of Action
R&D Progress
Rituximab + Carmustine + Cytarabine + Etoposide + Melphalan + Autologous Peripheral Blood Progenitor Transplantation
Product Description
Mechanism of Action
R&D Progress
rituximab + radiation theraphy
Product Description
Mechanism of Action
R&D Progress
Rituximab + Zevalin
Product Description
Mechanism of Action
R&D Progress
Sildenafil Citrate
Product Description
Mechanism of Action
R&D Progress
Sorafenib tosylate
Product Description
Mechanism of Action
R&D Progress
Talabostat
Product Description
Mechanism of Action
R&D Progress
Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Conjugate Vaccine + Sargramostim + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin
Product Description
Mechanism of Action
R&D Progress
Velcade + BEAM + Autologous Hematopoietic Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
17-N-Allylamino-17-Demethoxygeldanamycin
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Epirubicin + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Doxorubicin Hydrochloride + Topotecan Hydrochloride
Product Description
Mechanism of Action
R&D Progress
Gemcitabine Hydrochloride + Leucovorin Calcium + Fluorouracil + Nelfinavir Mesylate + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Imatinib Mesylate + Gemcitabine + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Tanespimycin
Product Description
Mechanism of Action
R&D Progress
University of Nebraska – Pipeline Analysis
University of Nebraska – Pipeline Products by Therapeutic Class
University of Nebraska Pipeline Products By Target
University of Nebraska – Pipeline Products by Route of Administration
University of Nebraska – Pipeline Products by Molecule Type
University of Nebraska - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
cyclosporine + mycophenolate + pentostatin + radiation theraphy
University of Nebraska – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1464032

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Sep 17th 2014
10:53:32 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

University of Nebraska - Developmental Therapeutics Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1464032

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Sep 17th 2014
10:53:32 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)